Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Both Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are progressive dementias characterized neuropathologically by the presence in the cerebral cortex of numerous neurofibrillary tangles and neuritic plaques. We use the abbreviation AD/SDAT to denote all such cases, irrespective of age of onset. Studies of neurotransmitter-related parameters in autopsied brain tissues from patients with AD/SDAT have, to date, been confined to five putative transmitter systems. Acetycholine-releasing neurones seem to be most markedly and consistently affected, as judged by the extensive reductions in choline acetyltransferase (ChAT) and acetylcholinesterase activities that have been reported. Despite numerous studies, there is no consistent evidence for the involvement of neurones releasing dopamine, noradrenaline, serotonin, or gamma-aminobutyric acid in AD/SDAT, nor for loss of muscarinic cholinergic receptors. Thus, the involvement of cholinergic neurones in AD/SDAT seems to be specific. However, the possible involvement of neurones using other chemicals as transmitters has yet to be explored. The recent recognition of the existence of so-called 'peptidergic neurones' in the mammalian brain (for review see ref. 8) and the availability of radioimmunoassay (RIA) techniques for studying these peptides, have led us to begin a systematic investigation of neuropeptides in autopsied brain tissue from cases of AD/SDAT, and from neurologically normal individuals. We report here results obtained with a RIA for somatostatin, showing that somatostatin-like immunoreactivity in the cerebral cortex is reduced in tissue from AD/SDAT patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ not only affects intracellular vesicular trafficking but could also affect primary cilia function directly or indirectly via its cognate binding receptors such as LRP1 [15, 50, 75].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“In addition, SST administration has been shown to be effective in improving cognitive impairment in AD patients [12, 15].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Dysfunctional SOMs have been identified as a hallmark of AD, and loss of SOMs in the cortex is associated with AD pathologies [10, 15, 65].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Additionally, AD patients have a specific loss of somatostatin-positive interneurons in the cortex [94] and hippocampus [95].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [94]
Citations
Cites
Hökfelt, T., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,547
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
Self-citationThe Prevalence and Malignancy of Alzheimer Disease: A Major Killer
Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040001001 · Cited by 619
Self-citationDementia of the Alzheimer Type
Terry, R. D., & Davies, P. (1980) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.03.030180.000453 · Cited by 529
Self-citationPrevalence and Malignancy of Alzheimer Disease
Lijtmaer, H., Fuld, P. A., & Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040088017 · Cited by 517
Self-citationNEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE
White, P., Goodhardt, M. J., Keet, J. P., Hiley, C. R., Carrasco, L. H., Williams, I. E. I., & Bowen, D. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92114-6 · Cited by 489
Davies, P., & Verth, A. H. (1977) · Brain Research · doi:10.1016/0006-8993(77)90758-2 · Cited by 313
Self-citationRadioimmunoassay for GH-Release Inhibiting Hormone
Arimura, A., Sato, H., Coy, D. H., & Schally, A. V. (1975) · Experimental Biology and Medicine · doi:10.3181/00379727-148-38631 · Cited by 302
Research works printed but not linked: 1
- Wisniewski, H. M. & Terry, R. D. in Neurobiology of Aging (eds Terry, R. D. & Gershon, S.) 265–280 (Raven, New York, 1976).
Cited by
Items 401–500 of 889
Does Scopolamine Directly Impair Memory?
Grober, E. H., Leipzig, R. M., Lipton, R. B., Wisniewski, W., Schroeder, M. M., Davies, P. J., Ritter, W., & Buschke, H. (1989) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.1989.1.4.327 · Cited by 35
Self-citationImmunohistochemical localization of the somatostatin sst4 receptor in rat brain
Selmer, I.-S., Schindler, M., Humphrey, P. P. A., & Emson, P. C. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00147-0 · Cited by 37
Regional distribution of neuropeptide somatostatin gene expression in the human brain
Mengod, G., Rigo, M., Savasta, M., Probst, A., & Palacios, J. M. (1992) · Synapse · doi:10.1002/syn.890120108 · Cited by 35
“Thus a decrease of SOM neurons in the cortex has been described (Davies et al., 1980; Gaspar et al., 1989) in the Alzheimer’s patients.”
Dementia in Parkinson’s Disease
Ruberg, M., & Agid, Y. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0933-8_5 · Cited by 44
Molchan, S. E., Hill, J., Mellow, A. M., LAWLOR, B. A., Martínez, R. A., & Sunderland, T. (1990) · International Psychogeriatrics · doi:10.1017/s1041610290000370 · Cited by 37
“Somatostatin (SS), which normally has an inhibitory effect on ACTH and CRH release, has been shown to be decreased in AD and in major depression (Davies et al., 1980; Rubinow, 1986; Sunderland et al., 1987).”
BackgroundHuang, X., Yee, B. K., Nag, S., Chan, S. T. H., & Tang, F. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00242-5 · Cited by 36
“The reported cholinergic and somatostatinergic deficits in AD patients (Davies, 1979; Davies et al., 1980) might therefore not be directly related to PS1 dysfunction/mutation.”
BackgroundPhenylethanolamine N‐methyltransferase (PNMT) gene and early‐onset Alzheimer disease
Mann, M. B., Wu, S., Rostamkhani, M., Tourtellotte, W. W., MacMurray, J. P., & Comings, D. E. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1363 · Cited by 35
Trophic Factors In Neurologic Disease
Stewart, S. S., & Appel, S. H. (1988) · Annual Review of Medicine · doi:10.1146/annurev.me.39.020188.001205 · Cited by 35
Neuropeptides and Alzheimer's Disease
Husain, M. M., & Nemeroff, C. B. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb05710.x · Cited by 37
GRIMALDI, M., Florio, T., & Schettini, G. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6513 · Cited by 35
Neuronal degeneration in human diseases and animal models
Price, D. L., Martin, L. J., Clatterbuck, R. E., Koliatsos, V. E., Sisodia, S. S., Walker, L. C., & Cork, L. C. (1992) · Journal of Neurobiology · doi:10.1002/neu.480230916 · Cited by 34
CSF Monoamine Metabolite Levels in Alzheimer's and Parkinson's Disease
Gibson, C. J., Logue, M. P., & Growdon, J. H. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060050091016 · Cited by 33
Vécsei, L., & Widerlöv, E. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06401.x · Cited by 33
Effect of naltrexone on senile dementia of the Alzheimer type.
Hyman, B. T., Eslinger, P. J., & Damasio, A. R. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.11.1169 · Cited by 33
Mizukawa, K., Vincent, S. R., McGeer, P. L., & McGeer, E. G. (1988) · Brain Research · doi:10.1016/0006-8993(88)90257-0 · Cited by 33
Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases
Whitford, C. A., Candy, J. M., Edwardson, J. A., & Perry, R. (1988) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(88)90003-2 · Cited by 37
Cutler, N. R., Haxby, J. V., Narang, P. K., May, C., Burg, C., & Reines, S. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503143121115 · Cited by 33
Neuropathology of the Aging Brain and Dementia of the Alzheimer Type
Wísniewski, H. M., & Merz, G. (1985) · Springer eBooks · doi:10.1007/978-1-4612-5058-6_20 · Cited by 34
Growth hormone neuroregulation and the clinical relevance of somatostatin
Wass, J. A. H. (1983) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(83)80061-9 · Cited by 33
Somatostatin, Olfaction, and Neurodegeneration
Saiz-Sanchez, D., Ubeda-Bañon, I., Flores-Cuadrado, A., Gonzalez-Rodriguez, M., Villar-Conde, S., Astillero-Lopez, V., & Martinez-Marcos, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00096 · Cited by 32
Age‐associated changes in hippocampal‐dependent cognition in Diversity Outbred mice
Koh, M. T., Spiegel, A. M., & Gallagher, M. (2014) · Hippocampus · doi:10.1002/hipo.22311 · Cited by 31
“Interestingly, postmortem studies of Alzheimer’s patients have shown reduced expression of somatosatin in the hippocampus and cortical areas (Davies et al., 1980; Beal et al., 1985, 1986; Dournaud et al., 1994), and the decreased expression was correlated with severity of cognitive deficits…”
BackgroundWatamura, N., Kakiya, N., Nilsson, P., Tsubuki, S., Kamano, N., Takahashi, M., Hashimoto, S., Sasaguri, H., Saito, T., & Saido, T. C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01368-8 · Cited by 34
Somatostatin and Cognitive Function in Neurodegenerative Disorders
Tuboly, G., & Vécsei, L. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955713804484794 · Cited by 33
“As regards SLI in the CSF, no change was found between ALS patients and normal subjects [168].”
BackgroundInfluentialActions of Excitatory Amino Acids on Somatostatin Release from Cortical Neurons in Primary Cultures
Tapia‐Arancibia, L., & ASTIER, H. S. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07406.x · Cited by 33
Dournaud, P., Jazat-Poindessous, F., Slama, A., Lamour, Y. A., & Epelbaum, J. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01231.x · Cited by 34
Neuropeptides, Behavior, and Aging
Morley, J. E. (1986) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1986.tb06340.x · Cited by 32
FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats
Tokita, K., Inoue, T., Yamazaki, S., Wang, F., Yamaji, T., Matsuoka, N., & Mutoh, S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.10.022 · Cited by 33
Implications of neuropeptides in neurological diseases
Sagar, S. M., Beal, M. F., Marshall, P. E., Landis, D. M. D., & Martin, J. B. (1984) · Peptides · doi:10.1016/0196-9781(84)90284-5 · Cited by 31
Evidence for increased amyloid enhancing factor activity in Alzheimer brain extract
Ali‐Khan, Z., Quirion, R., Robitaille, Y., Alizadeh-Khiavi, K., & Du, T. (1988) · Acta Neuropathologica · doi:10.1007/bf00688246 · Cited by 31
“AD has also been associated with extensive involvement of forebrain cholinergic nuclei [ 9 ].”
BackgroundSomatostatin-281–12-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex
Beal, M. F., Benoit, R., Mazurek, M. F., Bird, E. D., & Martin, J. B. (1986) · Brain Research · doi:10.1016/0006-8993(86)90586-x · Cited by 32
High-molecular-weight forms of somatostatin are reduced in Alzheimer's disease and Down's syndrome
Pierotti, A. R., Harmar, A. J., Simpson, J., & Yates, C. M. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90051-0 · Cited by 33
Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia.
Fujiyoshi, K., Suga, H., Okamoto, K., Nakamura, S., & Kameyama, M. (1987) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.50.7.929 · Cited by 35
Neuropathological and Neurochemical Aspects of Alzheimer’s Disease
Mann, D. M. A. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0933-8_1 · Cited by 40
Somatostatin and the pathophysiology of Alzheimer’s disease
Almeida, V. N. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102270 · Cited by 32
Neuropeptide levels in Alzheimer’s disease and dementia with frontotemporal degeneration
Minthon, L., Edvinsson, L. I., Ekman, R., & Gustafson, L. (1990) · Springer eBooks · doi:10.1007/978-3-7091-3345-3_6 · Cited by 30
Somatostatin-like immunoreactivity in the cerebrospinal fluid of neurological patients
Kohler, J., Schr�ter, E., & Cramer, H. (1982) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00343993 · Cited by 30
“Davies et al. (1980) found reduced somatostatin levels in the cerebral cortex of patients with presenile and senile dementia of Alzheimer's type.”
BackgroundKrantic, S. M., Martel, J.-C., Weissmann, D., Pujol, J. F., & Quirion, R. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90227-u · Cited by 32
Crespi, F. (1991) · Analytical Biochemistry · doi:10.1016/0003-2697(91)90152-j · Cited by 29
Pepeu, G., Casamenti, F., Pedata, F., Cosi, C., & Pepeu, I. M. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90024-2 · Cited by 29
Transgenic Mouse Models of Alzheimer's Disease and Amyotrophic Lateral Sclerosis
Borchelt, D., Wong, P. C., Sisodia, S. S., & Price, D. L. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00198.x · Cited by 30
“Levels of somatostatin, somatostatinergic binding sites, and corticotropin-releasing hormone are reduced in neocortex (15, 54), whereas binding sites for corticotropin-releasing factor are increased (56).”
AHMED, M., Hoshino, H., Chikuma, T., Yamada, M., & Kato, T. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.04.024 · Cited by 29
Neurotransmitters and Neuropeptides in Alzheimer's Disease
McDonald, W. M., & Nemeroff, C. B. (1991) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30316-2 · Cited by 31
The opioid system in neurologic and psychiatric disorders and in their experimental models
Gulya, K. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90026-x · Cited by 31
Pittaluga, A., Feligioni, M., Ghersi, C., Gemignani, A., & Raiteri, M. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00066-1 · Cited by 29
Neuropeptide modulation of central vestibular circuits.
Balaban, C. D., Starcevic, V. P., & Severs, W. B. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00023-7 · Cited by 31
Cholinergic Innervation in Cerebral Cortex
Eckenstein, F. P., & Baughman, R. W. (1987) · Cerebral cortex · doi:10.1007/978-1-4615-6616-8_3 · Cited by 29
Chapter 8 Neuropeptides and dementia
Rossor, M. N., Emson, P. C., Dawbarn, D., Mountjoy, C. Q., & Roth, M. (1986) · Progress in brain research · doi:10.1016/s0079-6123(08)64603-8 · Cited by 30
Yamashita, A., Fuchs, E., Taira, M., Yamamoto, T., & Hayashi, M. (2012) · Journal of Medical Primatology · doi:10.1111/j.1600-0684.2012.00540.x · Cited by 37
Nyitrai, G., Kékesi, K. A., Emri, Z., Szárics, É., Juhász, G. D., & Kardos, J. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.006 · Cited by 28
“It may be conjectured that somatostatin levels are decreased in Alzheimer’s disease patients (Davies et al., 1980; Grouselle et al., 1998), suggesting that increased levels of somatostatin may help to restore memory function.”
BackgroundBonanno, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00084-2 · Cited by 28
Age-related alterations of somatostatin gene expression in different rat brain areas
Florio, T., Ventra, C., Postiglione, A., & Schettini, G. (1991) · Brain Research · doi:10.1016/0006-8993(91)90116-d · Cited by 32
Effect of acute and chronic cholinesterase inhibition on biogenic amines in rat brain
Soininen, H. S., Unni, L. K., & Shillcutt, S. D. (1990) · Neurochemical Research · doi:10.1007/bf01208578 · Cited by 28
“In addition, several studies have shown deficiencies in a variety of different neuronal types, including noradrenergic, serotoninergic, dopaminergic, peptidergic, GABA-ergic and glutaminergic neurons ( 4-9 ) in brains of AD patients.”
Backgroundβ‐Amyloid increases somatostatin expression in cultured cortical neurons
Geci, C., How, J., Alturaihi, H., & Kumar, U. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04415.x · Cited by 29
“This parallels the pathology of AD, whereby a decrease in SSTLI neurons directly correlates with the severity of the disease (Davies et al. 1980; Wood et al. 1982; Beal et al. 1988; Bisette et al. 1998; Davis et al. 1999; Nemeroff 1999).”
BackgroundInfluentialUryu, K., Butler, A. K., & Chesselet, M.-F. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990308)405:2<216::aid-cne6>3.0.co;2-6 · Cited by 66
Environmental influence on somatostatin levels and gene expression in the rat brain
Nilsson, L. N. G., Mohammed, A. K., Henriksson, B. G., Folkesson, R., Winblad, B. G., & ̈m, L. B. (1993) · Brain Research · doi:10.1016/0006-8993(93)90942-g · Cited by 28
Neurotrophic factors and Alzheimer's disease
Wainer, B. H. (1989) · Neurobiology of Aging · doi:10.1016/0197-4580(89)90122-x · Cited by 28
Sandoval, K. E., Umbaugh, D. S., House, A., Crider, A. M., & WITT, K. A. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02890-6 · Cited by 28
Lu, M., Zhao, X., Xu, D.-E., Chen, J.-B., Ji, W., Huang, Z.-P., Pan, T.-T., Xue, L., Wang, F., Li, Q., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200010 · Cited by 30
“This observation is consistent with previous reports that decreased GABA + and SST + immunoreactivity have been observed in the cerebral cortex of AD patients [47, 48] and in apoE4 knock-in mice [18].”
Xue, S., Jia, L., & Jia, J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.09.002 · Cited by 27
Tokita, K. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00819-5 · Cited by 27
CSF somatostatin in obsessive-compulsive disorder
Altemus, M., Pigott, T. A., L'Heureux, F., Davis, C. L., Rubinow, D. R., Murphy, D. L., & Gold, P. W. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.3.460 · Cited by 27
Somatostatin replacement therapy for alzheimer dementia
Mouradian, M. M., Blin, J., Giuffra, M. E., Heuser, I. J. E., Baronti, F., Ownby, J., & Chase, T. N. (1991) · Annals of Neurology · doi:10.1002/ana.410300415 · Cited by 27
Schwartzberg, M., Unger, J. W., Weindl, A., & Lange, W. (1990) · Anatomy and Embryology · doi:10.1007/bf00198955 · Cited by 27
“In Alzheimer's disease, a consistent decrease of SOM-IR has been found in cortical regions (Davies et al. 1980), whereas NPY seems to be less affected (Beal et al.”
BackgroundTomidokoro, Y., Harigaya, Y., Matsubara, E., Ikeda, M., Kawarabayashi, T., Okamoto, K., & Shoji, M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01443-9 · Cited by 32
Yates, C. M., Fink, G., Bennie, J., Gordon, A., Simpson, J. A., & Eskay, R. L. (1985) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(85)90157-1 · Cited by 27
Age-Related Changes in Rat Hippocampal Theta Rhythms: A Difference between Type 1 and Type 2 Theta.
Abe, Y., & Toyosawa, K. (1999) · Journal of Veterinary Medical Science · doi:10.1292/jvms.61.543 · Cited by 29
“It is well known that the loss of basal forebrain cholinergic neurons is one of the most consistent and striking neuropathological features of Alzheimer’s disease [8, 10].”
BackgroundRecent research on the causes of Alzheimer's disease.
Deary, I. J., & Whalley, L. J. (1988) · BMJ · doi:10.1136/bmj.297.6652.807 · Cited by 32
Neuropeptides and Alzheimer's disease
Gottfries, C., Frederiksen, S. O., & Heilig, M. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)80009-q · Cited by 27
Sandoval, K. E., Farr, S. A., Banks, W. A., Niehoff, M. L., Morley, J. E., Crider, A. M., & WITT, K. A. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.12.013 · Cited by 26
“Decreases in the levels of somatostatin (somatotropin releaseinhibiting factor, SRIF) have been shown in the cerebral cortex and cerebrospinal fluid of Alzheimer's disease patients (Davies et al., 1980; Strittmatter et al., 1997).”
Age dependence of somatostatin levels and somatostatin binding in the rat brain
Sirviö, J., Jolkkonen, J., Pitkänen, A., & Riekkinen, P. J. (1987) · Comparative Biochemistry and Physiology Part A Physiology · doi:10.1016/0300-9629(87)90135-6 · Cited by 25
van der Zee, E. A., Benoit, R., Strosberg, A. D., & Luiten, P. G. M. (1991) · Brain Research Bulletin · doi:10.1016/0361-9230(91)90005-5 · Cited by 27
Vernadakis, A. (1985) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30960-1 · Cited by 28
Evaluation of an Analogue of Somatostatin (L363,586) in Alzheimer's Disease
(1985) · New England Journal of Medicine · doi:10.1056/nejm198503143121113 · Cited by 35
Somatostatin binding sites in various structures of the rat brain
Tapia‐Arancibia, L., Epelbaum, J., Enjalbert, A., & Kordon, C. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90201-6 · Cited by 25
Reduced Brain Somatostatin Levels in Alzheimer's Disease
Tamminga, C. A., Foster, N. L., & Chase, T. N. (1985) · New England Journal of Medicine · doi:10.1056/nejm198511143132017 · Cited by 25
Cardoso, A., Paula-Barbosa, M. M., & Lukoyanov, N. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.027 · Cited by 24
Kelley, M., & Kowall, N. W. (1989) · Brain Research · doi:10.1016/0006-8993(89)90657-4 · Cited by 27
The time of origin of somatostatin-immunoreactive neurons in the rat hippocampal formation
Rapp, P. R., & Amaral, D. G. (1988) · Developmental Brain Research · doi:10.1016/0165-3806(88)90185-x · Cited by 24
Somatostatin in neurodegenerative illnesses
Beal, M. F. (1990) · Metabolism · doi:10.1016/0026-0495(90)90226-3 · Cited by 27
Chemical Neuroanatomy of Alzheimer’s Disease
Saper, C. B. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0933-8_4 · Cited by 24
Neurotransmitter Receptor Alterations in Alzheimer’s Disease
Whitehouse, P. J., & Au, K. S. (1985) · Advances in applied neurological sciences · doi:10.1007/978-3-642-70644-8_14 · Cited by 24
Billová, S., Galanopoulou, A. S., Seidah, N. G., Qiu, X., & Kumar, U. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.04.039 · Cited by 23
Orikasa, C., Kondo, Y., & Sakuma, Y. (2006) · Endocrinology · doi:10.1210/en.2006-1214 · Cited by 27
Interneuron Progenitor Transplantation to Treat CNS Dysfunction
Chohan, M. O., & Moore, H. M. (2016) · Frontiers in Neural Circuits · doi:10.3389/fncir.2016.00064 · Cited by 24
“AD patients have been shown to have decreased GABA and SST immunoreactivity in the cerebral cortex (Davies et al., 1980; Grouselle et al., 1998), and in late-onset familial and sporadic AD, the risk gene apolipoprotein (apo) E4 polymorphism exacerbates SST dysfunction (Grouselle et al., 1998).”
BackgroundDysfunction and Death of Neurons in Human Degenerative Neurological Diseases and in Animal Models
Price, D. L., Cork, L. C., Struble, R. G., Kitt, C. A., Walker, L. C., Powers, R. E., Whitehouse, P. J., & Griffin, J. W. (2007) · Novartis Foundation symposium · doi:10.1002/9780470513422.ch3 · Cited by 24
Cholinergic Dysfunction in Alzheimer Disease: Cause or Effect?
Plotkin, D. A., & Jarvik, L. F. (1986) · Progress in brain research · doi:10.1016/s0079-6123(08)60644-5 · Cited by 24
Neurotransmitters of the Cerebral Cortex in Senile Dementia of Alzheimer Type
Rossor, M. N., Emson, P. C., Mountjoy, C. Q., Roth, M., & Iversen, L. L. (1982) · Experimental brain research. Supplementum · doi:10.1007/978-3-642-68507-1_21 · Cited by 23
Quantitative autoradiography of somatostatin receptors in the rat limbic system
Leroux, P., Weissmann, D., Pujol, J. F., & Vaudry, H. (1993) · The Journal of Comparative Neurology · doi:10.1002/cne.903310308 · Cited by 23
Choline uptake in patients with Alzheimer pre-senile dementia
Glen, A. I. M., Yates, C. M., Simpson, J., CHRISTIE, J. E., Shering, A., Whalley, L. J., & Jellinek, E. H. (1981) · Psychological Medicine · doi:10.1017/s0033291700052788 · Cited by 23
Hörtnagl, H., Sperk, G., Sobal, G., & Maas, D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01211.x · Cited by 23
“The decrease in the level of somatostatin in hippocampus and cerebral cortex in association with a profound cholinergic deficit is a consistent finding in postmortem brain studies of patients with Alzheimer’s disease (Davies et al., 1980; Beal et al., 1986~ ; Dawbarn et al., 1986; Chan-Palay, 1987).”
ResultOyelami, T., Bondt, A. D., den Wyngaert, I. V., Hoorde, K. V., Hoskens, L., Shaban, H., Kemp, J. A., & Drinkenburg, W. H. I. M. (2016) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2017-027 · Cited by 23
“This resulted in a list of 40 genes of interest: Cck – Cckar – Cckbr – Gabarap – Gabarapl1 – Gabbr1 – Gabra1 – Gabra2 – Gabra3 – Gabra4 – Gabra5 – Gabra6 – Gabrb1 – Gabrb2 – Gabrb3 – Gabrd – Gabre – Gabrg1 – Gabrg2 – Gabrg3 – Gabrp – Gabrq – Gabrr1 – Gabrr2 – Gad1 – Gad1os – Gad2 – Gadl1 – Slc32a1 – Slc6a1 – Slc6a11 –…”
BackgroundResultInfluentialGenotypic differences in central neurotransmitter responses to aging in mice
Ebel, A., Strosser, M. T., & Kempf, E. (1987) · Neurobiology of Aging · doi:10.1016/0197-4580(87)90036-4 · Cited by 22
Waters, S. M., & Davis, T. P. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb46142.x · Cited by 22
Kumar, U. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9093-3 · Cited by 25
“For instance, in AD, cortical and cerebrospinal fluid SST concentration is selectively reduced (Davies et al. 1980; Davis et al. 1988; Beal et al. 1985; Bissette and Myers 1992; Molchan et al. 1993; Nemeroff et al. 1992; Bissette et al. 1998; Nilsson et al. 2001).”
BackgroundThe neurochemistry of Alzheimer's disease and senile dementia
Davies, P. (1983) · Medicinal Research Reviews · doi:10.1002/med.2610030302 · Cited by 24
Self-citationNakagawasai, O., Tadano, T., Niijima, F., Tan–No, K., & Kisara, K. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(99)00201-4 · Cited by 23
Weiss, J. H., & Choi, D. W. (1991) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100032522 · Cited by 22
“Whether or not NMDA receptors are preferentially lost has been controversial.4344 We have raised the alternative speculation that any excitotoxic involvement in AD may be specifically mediated via non-NMDA receptors.45 The small subpopulation of cortical neurons containing somatostatin (SS), which as a population over…”
BackgroundFülöp, T., & Seres, I. (1994) · Drugs & Aging · doi:10.2165/00002512-199405050-00006 · Cited by 25
Blockade of a cardiac K+ channel by tacrine: interactions with muscarinic and adenosine receptors
Freeman, S. E., Lau, W., & Szı́lagyi, M. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90363-9 · Cited by 22
Polyadenylated Messenger RNA in Paired Helical Filament-Immunoreactive Neurons in Alzheimer Disease
Griffin, W. S. T., Ling, C., White, C. L., & Morrison‐Bogorad, M. (1990) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199004020-00001 · Cited by 22
Metadata
- Authors
- Davies, P., Katzman, R., & Terry, R. D.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Nature
- Published
- 1980-11
- Volume
- 288
- Issue
- 5788
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034969383
- Cited by
- 882
- References
- 9
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 20 · 2023: 18 · 2022: 11 · 2021: 11 · 2020: 19 · 2019: 8 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 9 · 2012: 8
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- Alzheimer's disease, senile dementia of the Alzheimer type, somatostatin, somatostatin-like immunoreactivity, cerebral cortex, neuropeptides, peptidergic neurons, neurotransmitter systems, cholinergic neurons, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Choline O-Acetyltransferase, Dementia, Humans, Middle Aged, Radioimmunoassay, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.